A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Public ClinicalTrials.gov record NCT03573817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease
Study identification
- NCT ID
- NCT03573817
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Mylan Inc.
- Industry
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Interventions
- Revefenacin Drug
- Placebo Drug
- Formoterol Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2018
- Primary completion
- Sep 24, 2018
- Completion
- Sep 24, 2018
- Last update posted
- Feb 23, 2022
2018
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Theravance Biopharma Investigational Site | Miami | Florida | 33155 | — |
| Theravance Biopharma Investigational Site | Orlando | Florida | 32825 | — |
| Theravance Biopharma Investigational Site | Sarasota | Florida | 34239 | — |
| Theravance Biopharma Investigational Site | Tampa | Florida | 33603 | — |
| Theravance Biopharma Investigational Site | Saint Charles | Missouri | 63301 | — |
| Theravance Biopharma Investigational Site | Monroe | North Carolina | 28112 | — |
| Theravance Biopharma Investigational Site | Columbus | Ohio | 43213 | — |
| Theravance Biopharma Investigational Site | Medford | Oregon | 97504 | — |
| Theravance Biopharma Investigational Site | Erie | Pennsylvania | 16508 | — |
| Theravance Biopharma Investigational Site | Gaffney | South Carolina | 29341 | — |
| Theravance Biopharma Investigational Site | Greenville | South Carolina | 29615 | — |
| Theravance Biopharma Investigational Site | Spartanburg | South Carolina | 29303 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03573817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2022 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03573817 live on ClinicalTrials.gov.